The introduction of mycophenolate mofetil to the treatment armamentarium for lupus nephritis raised the hope that the use of cyclophosphamide, with its toxic effects, would decrease. In this Review, the authors summarize the current knowledge of therapies for proliferative and membranous lupus nephritis and propose a treatment scheme, not of one therapy over another, but one that is tailored to the individual patient profile.
- George Bertsias
- Dimitrios T Boumpas